by Raynovich Rod | Jan 17, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Rally During #JPM23 Favors Smaller Caps Bolt-On acquisitions expected to bolster product pipelines. Macro headwinds lessened with moderating inflation. Small and mid-cap biotechs provide an innovation narrative. Here are some takeaways from #JPM23:...
by Raynovich Rod | Jan 12, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 1/13/23 Bank stocks beat with BAC and JPM trading higher. Bearish sentiment eroding as ” risk-on ” mentality takes hold before earnings. Continuing with #JPM Week Notes: 6. Continuing with the healthcare trend of more focused businesses and away...
by Raynovich Rod | Dec 19, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-4…1/6/23…Broad rally sparked by latest economic data anticipating weaker economy and slowing wage growth . Bond yields are down. A ‘”soft landing ‘”scenario? We are at the JPMorgan Healthcare Conference next week. Closing...
by Raynovich Rod | Nov 15, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 11/18…Healthcare stocks had a good week with the XLV up almost 1% to $134 despite choppiness. We are still facing MACRO headwinds and the FED so stay cautious. There was good tape action in mid-cap biopharmas. Medtech is looking better with the IHI up...
by Raynovich Rod | Oct 24, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 10/28… Broad rally after Megacaps sell-off -AMZN, META and MSFT. it almost look like the BIG tech money got spread around to energy, financials, and healthcare. In the meantime the DOW is up 5.69% for the week and 10.73% for the month led by AAPL...
by Raynovich Rod | Sep 26, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 Healthcare and Biotech Recap September Our strategic focus has been large cap biopharmaceuticals and healthcare (mainly UNH). Smaller caps have been a disappointment except for traders.The IWM is down 10% in one month! Some of our speculative picks are still...
by Raynovich Rod | Sep 15, 2022 | 2020-21 Life Science Portfolios, Biopharmaceuticals
Update-2 …9/22…3P EDT–Healthcare stocks trying to hold up: XLV up 0.69% up from recent lows of $122. NASDAQ down 1.62%. Weak sectors Consumer Discretionary, Financials , Industrials, Large cap biopharma and HC strong: ABBV, BMY, JNJ, MRK,PFE, REGN,...
by Raynovich Rod | Aug 28, 2022 | 2020-21 Life Science Portfolios, Macro
Update-1 Third Day this week of flailing around in the red, even AAPL down 1%. Small cap winners: EVH,MRTX, QDEL speculative ETFs: ARKG up 1.31%, XBI up 0.72% at $83.70 IBB flat at $121.46, XLV down 0.64% at $124.76. Notable biotech movers: CYTK up 3.78% at $52.96,...
by Raynovich Rod | Aug 14, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
8/25/22 Small caps are rallying. XBI is flat at the $89 handle but many of the picks below are up nicely:CRSP CYRX EVH VCYT. Market coming to Powell with speech tomorrow. Bears are wary of volatile seasonality and inflation data. Small cap strength:ARKG up 2.39%, IJR...
by Raynovich Rod | Aug 6, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-3 on JY 11 We will offer 3 updates in coming days: Healthcare Model, Large Cap Biopharma and Small/mid caps. Here are some notes on today’s market action: Momentum appears to be ebbing on profit taking.A bit of sector rotation into energy today with XLE...
